BMS and J&J's Librexia AF study is also comparing milvexian to Eliquis to see if it can prevent stroke and other clotting ...

For patients with acute coronary syndrome, targeted vitamin D3 supplementation is associated with a reduced risk for follow-up myocardial infarction.

Researchers sought to determine the most appropriate P2Y12 inhibitor therapy in patients with acute coronary syndrome.

Bristol Myers Squibb and Johnson & Johnson to discontinue phase 3 Librexia ACS trial of milvexian treat acute coronary syndrome: Princeton, New Jersey Monday, November 17, 2025, 1 ...

Milvexian’s failure in acute coronary syndrome dampens the outlook for other anticoagulants like it and is the latest in a ...

An acute coronary syndrome occurs when atherosclerotic coronary plaque becomes unstable, leading to a series of events eventually resulting in partial or total thrombotic occlusion of a coronary ...

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors—ticagrelor or prasugrel—in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025" report to their offering.

The United States is facing a demographic shift as the population of older adults grows rapidly, with the proportion of ...

Disruption of the fibrous cap on vulnerable atherosclerotic coronary plaques leads to exposure of the thrombogenic lipid core to the bloodstream, and is responsible for two-thirds of all coronary ...

A low dose of colchicine — a commonly used gout drug — helped reduce the risk of heart attack and stroke in people with ...